Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
News|Articles|October 10, 2023
Supporting the Mental Health Needs of Dermatology Patients
Author(s)Emma Andrus, Associate Editor
This World Mental Health Day, Dermatology Times is reviewing the important and often comorbid mental health concerns linked to common dermatologic conditions.
Advertisement
Advertisement
Related to this article
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
2
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5